- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting EphA2 in cancer
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-18
DOI
10.1186/s13045-020-00944-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level
- (2020) Jing Mo et al. CELLULAR ONCOLOGY
- Roles of EphA1/A2 and ephrin-A1 in cancer
- (2019) Katsuaki Ieguchi et al. CANCER SCIENCE
- EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer.
- (2019) Giulia Martini et al. MOLECULAR CANCER THERAPEUTICS
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
- (2019) Kohei Shitara et al. Journal for ImmunoTherapy of Cancer
- EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma
- (2019) Yige Fu et al. Pharmaceutics
- Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer
- (2019) HIROFUMI KUROSE et al. ANTICANCER RESEARCH
- Synergy between EphA2-ILs-DTXp, a novel EphA2 targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models
- (2019) Walid S. Kamoun et al. MOLECULAR CANCER THERAPEUTICS
- Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice
- (2019) Francesca Ferlenghi et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells
- (2018) ATSUSHI SAKAMOTO et al. ANTICANCER RESEARCH
- Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation
- (2018) Yuho Hamaoka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma
- (2018) Silvia Garcia-Monclús et al. INTERNATIONAL JOURNAL OF CANCER
- Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer
- (2018) Ning Li et al. Translational Oncology
- UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice
- (2018) Claudio Festuccia et al. Oncotarget
- EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma
- (2018) Hui Shi et al. Journal of Thoracic Disease
- Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
- (2018) Zhongzhen Yi et al. Molecular Therapy-Methods & Clinical Development
- Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer
- (2018) Tao Zhang et al. EBioMedicine
- Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
- (2017) Michael J. Wagner et al. MOLECULAR CANCER THERAPEUTICS
- First approval in sight for Novartis' CAR-T therapy after panel vote
- (2017) Cormac Sheridan NATURE BIOTECHNOLOGY
- EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells
- (2017) Elisabet Cuyàs et al. ONCOLOGY REPORTS
- Recent progress in development of siRNA delivery vehicles for cancer therapy
- (2016) Hyun Jin Kim et al. ADVANCED DRUG DELIVERY REVIEWS
- Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis
- (2016) Carmine Giorgio et al. BIOCHEMICAL PHARMACOLOGY
- Novel anti-EPHA2 antibody, DS-8895a for cancer treatment
- (2016) Jun Hasegawa et al. CANCER BIOLOGY & THERAPY
- EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
- (2016) Katherine R. Amato et al. CANCER RESEARCH
- The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer
- (2016) Victoria M. Youngblood et al. CANCER RESEARCH
- Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a
- (2016) I. J. G. Burvenich et al. JOURNAL OF NUCLEAR MEDICINE
- Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting
- (2016) Melissa L. Geddie et al. mAbs
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph–ephrin system
- (2015) Riccardo Castelli et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy
- (2015) Mahesh Jonnalagadda et al. MOLECULAR THERAPY
- Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
- (2015) D. J. DiLillo et al. Cancer Immunology Research
- UniPR129 is a competitive small molecule Eph-ephrin antagonist blockingin vitroangiogenesis at low micromolar concentrations
- (2014) I Hassan-Mohamed et al. BRITISH JOURNAL OF PHARMACOLOGY
- Generation and characterization of a single-chain anti-EphA2 antibody
- (2014) Yehuda Goldgur et al. GROWTH FACTORS
- Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC
- (2014) Katherine R. Amato et al. JOURNAL OF CLINICAL INVESTIGATION
- The immunomodulatory effect of propolis on receptors expression, cytokine production and fungicidal activity of human monocytes
- (2014) Michelle Cristiane Búfalo et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein-Protein Antagonists
- (2013) Massimiliano Tognolini et al. ChemMedChem
- CAR T cells: driving the road from the laboratory to the clinic
- (2013) Eleanor J. Cheadle et al. IMMUNOLOGICAL REVIEWS
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- Amino Acid Conjugates of Lithocholic Acid As Antagonists of the EphA2 Receptor
- (2013) Matteo Incerti et al. JOURNAL OF MEDICINAL CHEMISTRY
- Eph Receptor Signaling and Ephrins
- (2013) E. M. Lisabeth et al. Cold Spring Harbor Perspectives in Biology
- Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene
- (2012) Bhagyalaxmi Sukka-Ganesh et al. BMC CANCER
- Structure-Activity Relationships and Mechanism of Action of Eph-ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor
- (2012) Massimiliano Tognolini et al. ChemMedChem
- Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
- (2012) Christina M. Annunziata et al. INVESTIGATIONAL NEW DRUGS
- Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
- (2012) Geoffrey Porez et al. JOURNAL OF LIPID RESEARCH
- Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells
- (2012) Si Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
- (2012) Kevin KH Chow et al. MOLECULAR THERAPY
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- EphA2 Receptor Activation by Monomeric Ephrin-A1 on Supported Membranes
- (2011) Qian Xu et al. BIOPHYSICAL JOURNAL
- A Disalicylic Acid-Furanyl Derivative Inhibits Ephrin Binding to a Subset of Eph Receptors
- (2011) Roberta Noberini et al. Chemical Biology & Drug Design
- EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
- (2011) RONG Biao-xue et al. CURRENT CANCER DRUG TARGETS
- Polyphenol rich botanicals used as food supplements interfere with EphA2–ephrinA1 system
- (2011) Iftiin Hassan Mohamed et al. PHARMACOLOGICAL RESEARCH
- Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation
- (2011) Carmine Giorgio et al. PLoS One
- EphA receptor signaling—Complexity and emerging themes
- (2011) Hui Miao et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma
- (2010) J. W. Lee et al. CLINICAL CANCER RESEARCH
- Emerging strategies for EphA2 receptor targeting for cancer therapeutics
- (2010) Manish Tandon et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- EphA2Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation
- (2010) Leonardo Faoro et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Architecture of Eph receptor clusters
- (2010) J. P. Himanen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors
- (2009) Yongmun Choi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt
- (2009) Hui Miao et al. CANCER CELL
- EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
- (2009) Jeong-Won Lee et al. JNCI-Journal of the National Cancer Institute
- Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
- (2008) Q Chang et al. BRITISH JOURNAL OF CANCER
- Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity
- (2008) Shinjiro Yamaguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo
- (2008) D. Jackson et al. CANCER RESEARCH
- Eph-Ephrin Bidirectional Signaling in Physiology and Disease
- (2008) Elena B. Pasquale CELL
- Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
- (2008) R. Buettner et al. MOLECULAR CANCER RESEARCH
- The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
- (2008) J. Wykosky et al. MOLECULAR CANCER RESEARCH
- Targeting bile-acid signalling for metabolic diseases
- (2008) Charles Thomas et al. NATURE REVIEWS DRUG DISCOVERY
- Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor
- (2008) J Wykosky et al. ONCOGENE
- RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells
- (2008) Zhangming Zhou et al. SURGICAL NEUROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now